Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed

Affiliations

• ¹ Department of Pediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.
• ² Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
• ³ ACCELERATE, Brussels, Belgium.
• ⁴ Department of Paediatric and Adolescent Oncology, Institut Gustave Roussy and Paris-Saclay University, Villejuif, France.
• ⁵ Zoe4Life, Sullens, Switzerland.
• ⁶ Solving Kids' Cancer UK, London, United Kingdom.
• ⁷ Imagine for Margo, Saint-Germain-en-Laye, France.
• ⁸ University Medical Center Utrecht, Utrecht, the Netherlands.
• ⁹ Department of Pediatric Haematology/Oncology and Cell and Gene Therapy, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy.
• ¹⁰ AND Catholic University of the Sacred Heart, Rome, Italy.
• ¹¹ CAR T-cell Unit, Leukemia and Lymphoma Department, Pediatric Cancer Center Barcelona /Hospital Sant Joan de Déu, Barcelona, Spain.
• ¹² Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
• ¹³ The Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.
• ¹⁴ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
• ¹⁵ Pediatrics, Hematopoietic Stem Cell Transplantation Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
• ¹⁶ School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
• ¹⁷ Department of Pediatric Hematology and Oncology, Immunology and Stem Cell Transplantation, University Children's Hospital, Zurich, Switzerland.
• ¹⁸ Department of Pediatric Hemato-Immunology, Hôpital Universitaire Robert Debré (APHP and Université Paris Cité), Paris, France.